Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GM-CSF


Brief Information

Name:Macrophage colony stimulating factor 2
Target Synonym:GM-CSF,Molgramostin,CSF2,Colony Stimulating Factor 2,Sargramostim,GMCSF,CSF,Granulocyte Macrophage-Colony Stimulating Factor,Granulocyte-Macrophage Colony Stimulating Factor,Colony-Stimulating Factor,Granulocyte-Macrophage Colony-Stimulating Factor,Colony Stimulating Factor 2 (Granulocyte-Macrophage),Molgramostim
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:9
Lastest Research Phase:NDA/BLA

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

GMF-H4214-Cell-based assay

Human GM-CSF, premium grade(Cat. No. GMF-H4214) stimulates proliferation of GM-CSF-activated TF-1 cell. The specific activity of Human GM-CSF, premium grade is > 1.0ⅹ10^7 IU/mg , which is calibrated against human GM-CSF WHO International Standard (NIBSC code: 88/646) (QC tested).


Loaded Biotinylated Human GM-CSF, epitope tag free, primary amine labeling (Cat. No. GMF-H8214) on SA Biosensor, can bind Human GM-CSF R alpha, His Tag (SPR verified) (Cat. No. GRA-H52H7) with an affinity constant of 23.1 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).


Loaded Human GM-CSF R alpha, Fc Tag (Cat. No. GRA-H5255) on Protein A Biosensor, can bind Human GM-CSF, premium grade (Cat. No. GMF-H4214) with an affinity constant of 9.21 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name



Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PBI-1402 PBI-1402 Phase 2 Clinical Prometic Life Sciences Anemia Details
PD-360324 PD-360324; PD-0360324 Pfizer Pharmaceuticals Ltd (China) Details
SAR-441000 SAR441000; SAR-441000; BNT-131 Phase 1 Clinical Biontech Se, Sanofi Neoplasm Metastasis Details
Vusolimogene oderparepvec RP-1 Phase 2 Clinical Replimune Skin Melanoma; Carcinoma, Basal Cell; Carcinoma, Merkel Cell; Skin Neoplasms; Neoplasms; Microsatellite Instability; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Otilimab MOR-04357; GSK-3196165; GSK-165; MOR-103 Phase 3 Clinical University Of Melbourne Stomach Neoplasms; Arthritis, Rheumatoid; Spondylarthritis; Multiple Sclerosis; Severe Acute Respiratory Syndrome; Osteoarthritis Details
Plonmarlimab TJM-2; TJ-003234RAR101; TJ-003234 Phase 3 Clinical I-Mab Biopharma Co Ltd Macrophage Activation Syndrome; Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19) Details
MEDI-5395 MEDI-5395; MEDI5395 Phase 1 Clinical Medimmune Solid tumours; Neoplasms Details
Gimsilumab MORAb-022; KIN-1901 Phase 2 Clinical Morphotek Inc Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Rheumatic Diseases; Inflammation Details
BT-001 BT-001 Phase 2 Clinical Transgene Sa Solid tumours; Carcinoma, Merkel Cell; Triple Negative Breast Neoplasms; Neoplasms; Sarcoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasm Metastasis Details
Pexastimogene devacirepvec TG-6006; JX-594 Phase 2 Clinical Sillajen Inc, Regeneron Pharmaceuticals Inc, National Cancer Institute, Samsung Medical Center & Samsung Electronics Devices Llc Breast Neoplasms; Neoplasm Metastasis; Melanoma; Carcinoma, Hepatocellular; Lung Neoplasms; Lymphoma; Colorectal Neoplasms; Sarcoma; Neuroblastoma; Liver Neoplasms; Sarcoma, Ewing; Wilms Tumor; Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Ovarian Neoplasms; Rhabdomyosarcoma; Solid tumours Details
Namilumab MT-203; AMG-203; IZN-101 Phase 2 Clinical Takeda Pharmaceutical Co Ltd, Amgen Inc Arthritis, Rheumatoid; Sarcoidosis; Spondylitis, Ankylosing; Psoriasis; Sarcoidosis, Pulmonary Details
Bi-shRNAfurin and GMCSF augmented autologous tumor cell immunotherapy (Gradalis/Mary Crowley) IND-14205 Phase 3 Clinical Gradalis Inc Liver Neoplasms; Ovarian Neoplasms; Colonic Neoplasms; Breast Neoplasms; Sarcoma, Ewing; Genital Neoplasms, Female; Peritoneal Neoplasms; Uterine Neoplasms; Lung Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message